SE447450B - Farmaceutiska kompositioner med ihallande frigoring i tabellform samt sett att framstella dessa - Google Patents
Farmaceutiska kompositioner med ihallande frigoring i tabellform samt sett att framstella dessaInfo
- Publication number
- SE447450B SE447450B SE8100104A SE8100104A SE447450B SE 447450 B SE447450 B SE 447450B SE 8100104 A SE8100104 A SE 8100104A SE 8100104 A SE8100104 A SE 8100104A SE 447450 B SE447450 B SE 447450B
- Authority
- SE
- Sweden
- Prior art keywords
- tablet
- starch
- amount
- pharmaceutical composition
- cellulose
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title description 3
- 239000003826 tablet Substances 0.000 claims description 92
- 239000003795 chemical substances by application Substances 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 20
- 229920002678 cellulose Polymers 0.000 claims description 16
- 239000001913 cellulose Substances 0.000 claims description 16
- 235000010980 cellulose Nutrition 0.000 claims description 16
- 230000003628 erosive effect Effects 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 13
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 13
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 13
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 13
- 229920002261 Corn starch Polymers 0.000 claims description 12
- 229960002390 flurbiprofen Drugs 0.000 claims description 12
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229960001680 ibuprofen Drugs 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 229920000881 Modified starch Polymers 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 239000008120 corn starch Substances 0.000 claims description 8
- 235000019426 modified starch Nutrition 0.000 claims description 8
- -1 vinyl antacid Chemical class 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 235000019759 Maize starch Nutrition 0.000 claims description 4
- 239000004368 Modified starch Substances 0.000 claims description 4
- 229920002494 Zein Polymers 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 229940009868 aluminum magnesium silicate Drugs 0.000 claims description 4
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000440 bentonite Substances 0.000 claims description 4
- 229910000278 bentonite Inorganic materials 0.000 claims description 4
- 235000012216 bentonite Nutrition 0.000 claims description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 4
- 229920001592 potato starch Polymers 0.000 claims description 4
- 229940100486 rice starch Drugs 0.000 claims description 4
- 239000005019 zein Substances 0.000 claims description 4
- 229940093612 zein Drugs 0.000 claims description 4
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical group CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- 241000736873 Tetraclinis articulata Species 0.000 claims description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 239000007939 sustained release tablet Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 230000001458 anti-acid effect Effects 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 43
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 9
- 229960004889 salicylic acid Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-M chlorate Inorganic materials [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- DLWSRGHNJVLJAH-UHFFFAOYSA-N nitroflurbiprofen Chemical compound FC1=CC(C(C(=O)OCCCCO[N+]([O-])=O)C)=CC=C1C1=CC=CC=C1 DLWSRGHNJVLJAH-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11143080A | 1980-01-11 | 1980-01-11 | |
| US06/194,453 US4308251A (en) | 1980-01-11 | 1980-10-17 | Controlled release formulations of orally-active medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8100104L SE8100104L (sv) | 1981-07-12 |
| SE447450B true SE447450B (sv) | 1986-11-17 |
Family
ID=26808896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8100104A SE447450B (sv) | 1980-01-11 | 1981-01-09 | Farmaceutiska kompositioner med ihallande frigoring i tabellform samt sett att framstella dessa |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS56103110A (en)) |
| AT (1) | AT374681B (en)) |
| AU (1) | AU542824B2 (en)) |
| BE (1) | BE886998A (en)) |
| CA (1) | CA1140466A (en)) |
| CH (1) | CH646604A5 (en)) |
| DE (1) | DE3100191A1 (en)) |
| DK (1) | DK6181A (en)) |
| ES (2) | ES8205353A1 (en)) |
| FI (1) | FI76927C (en)) |
| FR (1) | FR2473308B1 (en)) |
| GB (1) | GB2067072B (en)) |
| GR (1) | GR73843B (en)) |
| IE (1) | IE50806B1 (en)) |
| IN (1) | IN151913B (en)) |
| IT (1) | IT1221041B (en)) |
| LU (1) | LU83052A1 (en)) |
| NL (1) | NL8100037A (en)) |
| NO (1) | NO156153C (en)) |
| NZ (1) | NZ195933A (en)) |
| SE (1) | SE447450B (en)) |
| ZA (1) | ZA81136B (en)) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2496082A (en) * | 1947-05-24 | 1950-01-31 | Ashenfelter William | Scaffold structure |
| IT1144911B (it) * | 1981-03-19 | 1986-10-29 | Pharmatec Spa | Composizione farmaceutica a rilascio controllato contenente ibuprofen |
| JPS59227817A (ja) * | 1983-06-07 | 1984-12-21 | Toyo Jozo Co Ltd | 持続性経口用ブレデニン製剤 |
| JPH0662404B2 (ja) * | 1983-06-14 | 1994-08-17 | シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド | 制御放出性ナプロキセンおよびナプロキセンナトリウム錠 |
| ZA836030B (en) * | 1983-08-16 | 1985-02-27 | Verex Lab | Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions |
| ZA836031B (en) * | 1983-08-16 | 1985-02-27 | Verex Lab | Constant release rate solid dosage theophylline formulation |
| US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
| US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
| EP0138216B1 (en) * | 1983-10-14 | 1993-01-07 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release ifn preparation for parenteral administration |
| US4855134A (en) * | 1983-10-14 | 1989-08-08 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release preparation |
| ATE87469T1 (de) * | 1985-12-27 | 1993-04-15 | Sumitomo Pharma | Verfahren zur herstellung einer formulierung mit verzoegerter freisetzung. |
| GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| ZA881301B (en) * | 1987-02-27 | 1989-10-25 | Lilly Co Eli | Sustained release matrix formulations |
| AU6403196A (en) | 1995-06-30 | 1997-02-05 | Baylor University | Polyester/carboxylic acid composite materials |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953497A (en) * | 1953-06-03 | 1960-09-20 | Howard A Press | Therapeutic tablets |
| BE604564A (en)) * | 1960-06-06 | |||
| US3577514A (en) * | 1968-06-10 | 1971-05-04 | Pfizer | Sustained release pharmaceutical tablets |
| US3773920A (en) * | 1971-07-14 | 1973-11-20 | Nikken Chemicals Co Ltd | Sustained release medicinal composition |
| US3906086A (en) * | 1971-07-19 | 1975-09-16 | Richard G Powers | Timed-release aspirin |
| GB1500300A (en) * | 1975-01-06 | 1978-02-08 | Ciba Geigy Ag | Pharmaceutical preparation for the treatment of circulatory disorders |
| JPS5411226A (en) * | 1977-06-24 | 1979-01-27 | Shin Etsu Chem Co Ltd | Disintegratable granule |
-
1980
- 1980-12-23 IN IN1418/CAL/80A patent/IN151913B/en unknown
- 1980-12-23 NZ NZ195933A patent/NZ195933A/xx unknown
-
1981
- 1981-01-05 AU AU65976/81A patent/AU542824B2/en not_active Ceased
- 1981-01-06 FR FR8100087A patent/FR2473308B1/fr not_active Expired
- 1981-01-07 DE DE19813100191 patent/DE3100191A1/de active Granted
- 1981-01-07 NL NL8100037A patent/NL8100037A/nl not_active Application Discontinuation
- 1981-01-08 BE BE0/203426A patent/BE886998A/fr unknown
- 1981-01-08 GB GB8100522A patent/GB2067072B/en not_active Expired
- 1981-01-08 JP JP157881A patent/JPS56103110A/ja active Pending
- 1981-01-08 ES ES498369A patent/ES8205353A1/es not_active Expired
- 1981-01-08 DK DK6181A patent/DK6181A/da not_active Application Discontinuation
- 1981-01-08 CH CH9281A patent/CH646604A5/fr not_active IP Right Cessation
- 1981-01-09 IT IT47537/81A patent/IT1221041B/it active
- 1981-01-09 AT AT0005481A patent/AT374681B/de not_active IP Right Cessation
- 1981-01-09 CA CA000368219A patent/CA1140466A/en not_active Expired
- 1981-01-09 IE IE36/81A patent/IE50806B1/en unknown
- 1981-01-09 SE SE8100104A patent/SE447450B/sv not_active IP Right Cessation
- 1981-01-09 ZA ZA00810136A patent/ZA81136B/xx unknown
- 1981-01-09 GR GR63828A patent/GR73843B/el unknown
- 1981-01-09 LU LU83052A patent/LU83052A1/fr unknown
- 1981-01-09 NO NO810062A patent/NO156153C/no unknown
- 1981-01-09 FI FI810056A patent/FI76927C/fi not_active IP Right Cessation
-
1982
- 1982-01-29 ES ES509179A patent/ES509179A0/es active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| AT374681B (de) | 1984-05-25 |
| IE810036L (en) | 1981-07-11 |
| NO156153B (no) | 1987-04-27 |
| NZ195933A (en) | 1982-11-23 |
| FR2473308B1 (fr) | 1985-07-19 |
| GB2067072B (en) | 1983-08-10 |
| ZA81136B (en) | 1982-01-27 |
| CA1140466A (en) | 1983-02-01 |
| GR73843B (en)) | 1984-05-07 |
| NO156153C (no) | 1987-08-05 |
| FR2473308A1 (fr) | 1981-07-17 |
| GB2067072A (en) | 1981-07-22 |
| FI810056L (fi) | 1981-07-12 |
| NL8100037A (nl) | 1981-08-03 |
| JPS56103110A (en) | 1981-08-18 |
| IT8147537A0 (it) | 1981-01-09 |
| ES8301629A1 (es) | 1982-12-16 |
| LU83052A1 (fr) | 1982-09-10 |
| ATA5481A (de) | 1983-10-15 |
| NO810062L (no) | 1981-07-13 |
| DE3100191C2 (en)) | 1988-09-01 |
| ES498369A0 (es) | 1982-06-01 |
| ES8205353A1 (es) | 1982-06-01 |
| DK6181A (da) | 1981-07-12 |
| SE8100104L (sv) | 1981-07-12 |
| AU542824B2 (en) | 1985-03-14 |
| ES509179A0 (es) | 1982-12-16 |
| CH646604A5 (fr) | 1984-12-14 |
| BE886998A (fr) | 1981-07-08 |
| IE50806B1 (en) | 1986-07-23 |
| FI76927B (fi) | 1988-09-30 |
| IT1221041B (it) | 1990-06-21 |
| DE3100191A1 (de) | 1981-12-10 |
| IN151913B (en)) | 1983-09-03 |
| AU6597681A (en) | 1981-07-16 |
| FI76927C (fi) | 1989-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE447450B (sv) | Farmaceutiska kompositioner med ihallande frigoring i tabellform samt sett att framstella dessa | |
| AU662239B2 (en) | Controlled release morphine preparation | |
| US3965256A (en) | Slow release pharmaceutical compositions | |
| US3632739A (en) | Solid sustained release pharmaceutical preparation | |
| EP0255404B1 (en) | Sustained release ibuprofen formulation | |
| JPH08500110A (ja) | ブプロピオン含有持続放出型錠剤 | |
| US4867987A (en) | Pharmaceutical product for the sustained release of ibuprofen | |
| EP0025686B1 (en) | Pharmaceutical composition containing paracetamol, treatment pack comprising said composition and method of reducing liver toxicity effect of paracetamol compositions | |
| AU2002213900A1 (en) | Pharmaceutical compositions | |
| WO2002020090A2 (en) | Pharmaceutical compositions | |
| JPH03500288A (ja) | 徐放性ニフェジピン製剤 | |
| Rahul et al. | A review on immediate release drug delivery systems | |
| CA2063689C (en) | Ibuprofen lysinate pharmaceutical formulation | |
| WO2003059323A2 (de) | Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren ii | |
| CN105407875A (zh) | 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法 | |
| CN102988357B (zh) | 一种复方α酮酸药物组合物及其制备方法 | |
| Brkich et al. | Scientific and Methodical approach to developing the formulation of an Innovative Medicinal Product based on a derivative of 3, 7-diazabicyclo [3.3. 1] nonane (hydrindane) | |
| AU2014295099A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| JP2003221326A (ja) | 分岐鎖アミノ酸を含有するチュアブル剤 | |
| JPH05194233A (ja) | マイクロペレットおよびそれらの製造方法 | |
| JPH0797325A (ja) | 安定な固形製剤およびその製造法 | |
| JP4064493B2 (ja) | ビタミン類含有組成物 | |
| JPH04368330A (ja) | ペミロラストカリウムの徐放性製剤 | |
| JPH11322584A (ja) | ベザフィブラート徐放性製剤 | |
| JP4845087B2 (ja) | 経口投与用製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8100104-2 Effective date: 19901211 Format of ref document f/p: F |